該当箇所へ

ポスター:ウィルス/非ウィルスベクターの生産自動化による新たな細胞・遺伝子治療の開発加速

ESACT, Edinburgh
June 23, 2024

CGTs revolutionize medicine by providing personalized treatments for a wide range of diseases. These therapies can restore gene function and transfer new genetic material to a patient’s cells to treat, prevent, or cure diseases.CGT R&D faces several challenges, including functional complexity, registering, monitoring, controlling, and evaluating production processes, and streamlining data management. Despite these challenges, the industry has shown enormous potential. Efficient production of one of the main actors of CGTs, viral vectors, is a crucial step in CGT R&D. Streamlined data management of highly complex, automated, and high-throughput processes is crucial for optimizing processes and workflows and for accelerating the identification of therapeutic CGT candidates. We have therefore developed a platform that helps register viral vectors and monitor, control, and evaluate all laboratory production processes. It helps streamline the development process, reduce costs, and improve efficiency. It also helps with data analysis and workflow challenges posed by increased assay throughput and organizational growth. We have developed a digital platform that facilitates the development of next-generation bio-manufacturing processes such as CGTs. The platform is modular, scalable, and easy to integrate, allowing flexible configuration for specific workflows like proprietary expression and purification protocols, emerging discovery workflows, or analytical technologies. The platform is purpose-built for digitalizing next-generation process design and achieving operational excellence in the development of biotherapeutic drugs. Designed to enforce data integrity and compliance and to streamline the development of originator drugs and biosimilars, it is globally used by pharmaceutical giants and renowned CMOs to increase the efficiency of their development processes.


資料をリクエスト

本フォームを送信することで、Genedata プライバシーポリシー に従い個人情報が収集・利用されることへ同意します。